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Abstract
Although corticospinal tract axons cannot regenerate long distances after spinal cord injury, they are able to sprout
collateral branches rostral to an injury site that can help form compensatory circuits in cases of incomplete lesions.
We show here that inosine enhances the formation of compensatory circuits after a dorsal hemisection of the thoracic
spinal cord in mature rats and improves coordinated limb use. Inosine is a naturally occurring metabolite of
adenosine that crosses the cell membrane and, in neurons, activates Mst3b, a protein kinase that is part of a signal
transduction pathway that regulates axon outgrowth. Compared to saline-treated controls, rats with dorsal
hemisections that were treated with inosine showed three times as many synaptic contacts between corticospinal
tract collaterals and long propriospinal interneurons that project from the cervical cord to the lumbar level. Inosine-
treated rats also showed stronger serotonergic reinnervation of the lumbar cord than saline-treated controls, and
performed well above controls in both open-field testing and a horizontal ladder rung-walking test. Inosine was
equally effective whether delivered intracranially or intravenously, and has been shown to be safe for other
indications in humans. Thus, inosine might be a useful therapeutic for improving outcome after spinal cord injury.
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Introduction
Spinal cord injury (SCI) can result in devastating, irreversible
losses of sensory, motor, and/or autonomic function due to the
interruption of connections between higher brain centers and
segments of the spinal cord below the level of injury. Multiple
factors normally prevent these pathways from regenerating,
and in animal models of SCI, significant improvements have
been achieved by counteracting inhibitory molecules
associated with myelin and the glial scar, inserting stem cell
bridges and/or biopolymer scaffolds, providing growth factors
or cAMP analogs, altering gene expression, and/or increasing
physiological activity [1-8]. However, this research has not yet
led to novel therapeutic interventions and some of these
approaches carry potential risks.
Although long-distance regeneration remains a major
challenge, the corticospinal tract (CST) and other major
pathways can form compensatory circuits after incomplete
lesions. Transection of the CST at the thoracic level causes
severed axons to sprout collateral branches at the cervical
level that synapse onto long propriospinal interneurons
(LPSNs), forming “detour circuits” that restore some cortical
control to the hindlimbs [9-11]. Undamaged CST axons can
also form collateral branches that contribute to recovery [12].
Thus, agents that promote sprouting may help improve
outcome after partial lesions of the spinal cord.
One such agent is inosine, a naturally occurring derivative of
adenosine. Inosine diffuses into neurons and activates Mst3b,
a protein kinase that is part of a signal transduction pathway
that regulates axon growth [13,14]. Inosine induces outgrowth
in several types of neurons in culture and, when infused into
the brain after unilateral cortical injury, enables CST axons that
arise from the undamaged hemisphere to extend collateral
branches into the denervated side of the spinal cord [13,15-21].
The present study investigated whether inosine can augment
the formation of detour circuits and improve functional outcome
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after transecting the CST and other pathways in the dorsal
spinal cord of mature rats. We report that inosine more than
tripled the formation of CST synapses onto LPSNs in the
cervical cord after a dorsal hemisection at the thoracic level,
increased raphespinal sprouting, and markedly improved fine
motor coordination as well as general locomotion. Inosine was
equally effective whether given intravenously or intracerebrally.
Because of its safe history of use in humans for other
indications, inosine is an attractive candidate for clinical trials in
SCI patients.
Materials and Methods
Ethics Statement
All procedures were performed in accordance with NIH
guidelines and were approved by Boston Children’s Hospital’s
Institutional Animal Care and Use Committee (IACUC, protocol
13-04-2373R). All animals used in the study were anesthetized
by either a Ketaset/dexdormitor cocktail (dosages below) or
isoflurane and were maintained in a deep state of anesthesia
throughout all surgical procedures. Animals were euthanized
with an overdosed by isoflurane prior to transcardial perfusion
(details below). All efforts were made to minimize suffering.
Spinal Cord Surgery
Adult male Sprague Dawley rats (250-300 g; Charles River
Laboratories) were maintained on a 12 h light/dark cycle.
Experimental and control cases were generated on a random
basis, and the subsequent analyses of behavior and anatomy
were blinded. Animals included in the study were generated
over a course of 2 years, with no more than two surgeries on a
single day. Rats were anesthetized with Ketaset (ketamine, 75
mg/kg, s.c.; Fort Dodge) and dexdormitor (dexmedetomidine,
0.25 mg/kg, s.c.; Pfizer), and a skin incision was made at the
T8 level. Muscles were cut in layers along the midline and
retracted under a surgical microscope. A laminectomy was
performed at the T8 level. Lidocaine-HCl (10 mg/ml; Hospira)
was applied topically to the spinal cord to minimize pain and
sensation during surgery. The dura mater was opened and
removed using #3 jewelers’ forceps and a #11 scalpel blade.
The dorsal half of the spinal cord was transected using a #11
scalpel blade to a depth of 1.1 mm. Transection of the dorsal
CST was confirmed visually and subsequently verified
histologically. Gelfoam was packed into the injury site and
muscles were closed in layers using 3-0 silk sutures. Sham-
operated animals served as normal controls and underwent all
procedures up to the point of the dorsal hemisection and pump
placement.
Osmotic Minipumps
Immediately after spinal cord surgery, rats were fitted with
Alzet osmotic minipumps to deliver saline or inosine either
intracerebroventricularly (i.c.v.) or intravenously (i.v.).
Minipumps were prepared the day before for priming per the
manufacturer’s instructions (Durect). Animals receiving i.c.v.
treatment had a borehole drilled over the lateral ventricle of the
right hemisphere (coordinates: 0.08 cm A/P, 0.14 cm M/L
relative to bregma) and an Alzet brain infusion needle (Brain
Infusion Kit 2; Durect) was inserted to a depth of 5.0 mm and
secured using a silicon-based glue. The brain infusion kit was
attached to an osmotic pump (Alzet 2002; Durect) that was
placed subcutaneously behind the shoulder blades. Animals in
all experiments were assigned on a random basis to receive
either saline (0.9%, Baxter) or inosine (50 mM in saline, Sigma-
Aldrich) at a flow rate of 0.5 µl/hour (~ 0.5 mg/kg body weight/
day). Pumps were replaced biweekly.
For intravenous (i.v.) delivery, rats were purchased from
Charles River Laboratories with pre-fitted jugular vein
catheters. Immediately after surgery, rats were fitted with Alzet
osmotic pumps (2ML1, Durect) attached to the catheters to
deliver saline or inosine (260 mM, ~ 70 mg/day/kg body
weight). In a subsequent dose-response study, rats also
received i.v. inosine at either 30 or 100 mM (8 - 27 mg/day/kg
body weight). Pumps were changed weekly. To ensure that
catheters remained functional, they were flushed weekly during
the pump change with heparin lock flush (100 USP Units/ml,
APP Pharmaceuticals). Inosine solubility increases with
elevated pH, and we adjusted the pH of both the inosine and
vehicle (saline) solutions to 9.2 to allow solubilization of the
highest concentration used. Intravenous delivery of inosine
elevates cerebrospinal fluid concentrations within 45 minutes of
beginning infusion (Hurtt et al., U.S. Patent 20090221521).
Following pump placement, the skin was closed with 3-0 silk
sutures and rats were allowed to recover on a warming pad
before being returned to the animal facility. All animals were
given Buprenex (0.05 mg/kg, s.c.; buprenorphine; Bedford
Laboratories) every 8-12 hours for 72 hr and the antibiotic
Enrofloxacin (2.5 mg/kg, s.c., Bayer) daily for one week.
Bladders were expressed manually twice daily until voluntary
control was restored. Rats received subcutaneous boluses of
lactated Ringer’s solution twice daily for 2 weeks to maintain
hydration.
Behavioral Testing
Rats were tested for general locomotion using the Basso,
Beattie, Bresnahan (BBB) scale [22] and for skilled use of the
hindlimbs using the horizontal ladder rung walking test [23].
The BBB was evaluated at 24 hours and 7 days after surgery
and then weekly over a 4-week period. Two observers were
trained to assess hindlimb function according to standard
criteria [22] and scored each behavioral exam independently.
The number of rats tested in Study I was: saline (combined i.v.
and i.c.v.), n = 14; inosine i.c.v., n = 10; inosine i.v., n = 8. In
Study II: saline i.v., n = 14; inosine i.v., n = 20. The same rats
were evaluated for skilled use of the hindlimbs using a
horizontal ladder rung walking test the week after spinal cord
surgery and every week after that over the 4-week period (n
values same as above). This task assesses sensorimotor
coordination and requires descending cortical control [23].
Animals were placed on a horizontal ladder 14 cm wide and
100 cm long suspended 30 cm above the surface. Rungs were
spaced irregularly at 2 - 5 cm intervals to prevent rats from
learning a fixed pattern of stepping. Performance was video-
recorded and scored later (successful steps/total steps) by lab
members blind to animals’ treatments. Unsuccessful steps are
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as defined by Metz and Whishaw [23], where a hindlimb either
misses a rung completely or initially makes contact with a rung
but slips during weight-bearing.
Anatomical Tracing
Twenty-eight days after SCI, animals received bilateral
injections of the anterograde tracer biotinylated dextran amine
(BDA, 10,000 MW, 10% w/v solution in sterile saline;
Invitrogen) into 9 sites within the hindlimb motor area under
stereotaxic guidance. In the first study, BDA placement was
guided by the boundaries of the hindlimb area shown in a
standard rat brain atlas [24]. We subsequently discovered,
however, that these injections infringed upon the forelimb area,
causing considerable labeling of CST axons that normally
project to the cervical spinal cord. This labeling made it difficult
to assess the sprouting of hindlimb CST fibers after SCI, and
we therefore modified the injection coordinates based on an
electrophysiological mapping study of the motor cortex [25]
(new coordinates in cm with respect to bregma: 0.05 A/P, ±
0.10 M/L; 0.00 A/P, ± 0.10 M/L; 0.00 A/P, 0.0 M/L; -0.05 A/P, ±
0.10 M/L; -0.05 A/P, ± 0.15 M/L; -0.10 A/P, ± 0.10 M/L; -0.10
A/P, ± 0.15 M/L). BDA injections (Nanoject II, Drummond
Scientific) were placed at 3 different depths (2.0 mm, 1.0 mm,
0.5 mm, 1 min each) for each injection site. Retrograde labeling
of long propriospinal interneurons was carried out by injecting 1
µl of Cholera Toxin Subunit B (CTB; 1%; List Biological) into
each side of the lumbar spinal cord (level L2 – L3) using a
glass micropipette and Nanoject II (200-300 µm lateral to
midline; ~ 400 µm depth). Micropipettes remained in place for 1
min after injections. The skin and muscles were then sutured
closed and rats recovered on a warming pad before returning
to their cages. Two weeks later, rats were euthanized with an
overdose of anesthesia and perfused transcardially with 0.9%
saline followed by 4% paraformaldehyde (PFA). The brain and
spinal cord were post-fixed in 4% PFA overnight (4°C) and
cryoprotected in sucrose (10% for 24 h, then 30% for 24 h). A 2
cm segment of the thoracic spinal cord centered around the
lesion site was embedded in gelatin-albumin (Type-A; Sigma-
Aldrich) and cut at 40 µm in the parasagittal plane using a
Vibratome. The brain and portions of the cervical and lumbar
spinal cord were embedded in Tissue-Tek (Sakura Finetek
USA) and frozen (–20°C) for cryostat sectioning. Although rats
from the first study were not analyzed for axon sprouting, they
were analyzed for behavior, lesion depth, and serotonergic
reinnervation, which are unaffected by the tracer injections.
Visualization of BDA injections
Free-floating sections through the forebrain (coronal plane,
40 µm thick) were reacted with avidin-biotin complex
conjugated to horseradish peroxidase (Vectastain ABC Kit,
Vector) followed by a DAB-peroxidase substrate kit (Vector).
Sections were mounted onto slides (Superfrost Plus; VWR),
dried, rehydrated through graded ethanol solutions, stained
with Cresyl Fast Violet (Certified; Ted Pella, Inc.), dehydrated
through serial ethanol solutions and xylene, and covered using
Permount (Fisher). BDA placement was confirmed
anatomically in each rat by reference to a standard brain atlas
[24]. The observation that very few CST fibers were labeled in
the cervical enlargement of sham-operated controls provides
further evidence that our BDA injections did not infringe into the
forelimb motor area.
Lesion Depth and Area
The cross-sectional area of the lesion and width of the
remaining tissue bridge were measured using NIH ImageJ
software (Wayne Rasband, NIH, Bethesda, MD), averaging the
results from several sections close to the midline. To further
verify that we had transected the CST, free-floating coronal
sections at the cervical and lumbar levels (40 µm) were stained
to visualize BDA-positive axons as above. Rats were excluded
from the study if (i) spared tissue at the center of the lesion was
either ≤ 15% or ≥ 50% the width of the spinal cord (measured
in adjacent uninjured areas); or if (ii) BDA-positive fibers were
seen in the dorsal CST in the lumbar region. These criteria
excluded rats with lesions that spared fibers in the principal
(dorsomedial) CST or that were too large to allow functional
recovery (see below). Lesion area is presented as the
percentage of tissue that was lost or necrotic in an area
spanning 4 mm on either side of the lesion epicenter.
CST Sprouting
Coronal sections through levels C3 – C5 were stained to
visualize BDA-positive axons as above. We identified the
midline using the central canal and dorsal median fissure as
landmarks, then quantified the number of BDA-positive axon
profiles ≥ 50 μm in length within the gray matter at the edge of
the dorsal CST, at the midline (M), and at two fixed distances
from the midline labeled Zones I and II (see below). Zone I was
defined by lines parallel to the midline passing through the
lateral edges of the dorsal CST on either side, whereas Zone II
included virtual lines at twice this distance from the midline.
Results were averaged over 12-20 sections and were
normalized by the total number of labeled axons in the dorsal
CST for each case. This latter number was established by
staining 10 coronal sections through the cervical enlargement
with fluorescently tagged strepavidin-biotin complex
(Strepaviden Alexa Fluor 647, Invitrogen) and capturing digital
images through 3 µm optical sections (Ultraview Vox Spinning
Disk confocal microscope). Axons, which appear as dots in the
coronal plane, were quantified using Stereo Investigator (MBF
Bioscience) and averaged across the 10 sections to determine
the number of labeled axons in the CST for each case.
CST contacts onto LPSNs
Free-floating sections through cervical levels C3-C5 were
blocked with a solution containing 3% bovine serum albumin
(BSA) and 10% normal goat serum (NGS) in PBS with 0.5%
Triton X-100, then incubated in a rabbit anti-CTB antibody
(1:10,000, Genway) in a similar buffer but with 5% NGS
overnight at 4°C. Sections were rinsed and incubated with goat
anti-rabbit IgG conjugated to Alexa Fluor 594, 1:500, and
Strepavidin conjugated to Alexa Fluor 647, 1:1000 (Invitrogen).
Digital images of all CTB-positive cells (typically 4-7 per
section, avg. 45/case) were captured in 10-12 sections, and the
number of BDA-labeled boutons, defined as swellings at least
twice the thickness of the axon [26] falling on or within 20 µm of
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a CTB-labeled soma or dendrite, were quantified using the
Stereo Investigator program. All CTB-labeled somata were
counted and results are presented as the number of BDA-
positive contacts onto CTB-positive LPSNs per section
normalized by the number of BDA-positive axons in the CST
and averaged over the experimental group.
Synaptophysin-positive contacts
A separate set of free-floating sections through the cervical
enlargement was rinsed in PBS, transferred to a preheated
solution of 10 mM sodium citrate (pH 8.5, 80° C, 30 min), then
to 3% H2O2 in methanol (10 min), blocked with 5% NGS in
PBS, and incubated overnight with a monoclonal anti-
synaptophysin antibody (1:200, Millipore) in PBS containing 3%
Triton X-100 at 4°C. Sections were rinsed in PBS and
incubated in an Alexa Fluor 488-conjugated antibody to mouse
IgG (made in goat: Invitrogen) in 0.3% Triton X-100 in PBS and
for 2 h, RT. Sections were rinsed and stained for BDA in
presynaptic axons and CTB in long propriospinal interneurons
as above. Sections were then mounted and covered. Stacked
images were collected in the vicinity of all CTB-positive cell
bodies (Ultraview Vox confocal) and transferred to the Stereo
Investigator software. This enabled us to quantify (i) total BDA-
positive bouton-like swellings, (ii) total BDA+ boutons that were
double-stained for synaptophysin, and (iii) Synaptophysin-
positive, BDA-positive terminals that fell on or within 20 µm of
CTB-positive long propriospinal interneurons. Results were
averaged over 10-12 sections and normalized by the total
number of BDA-positive axons in the CST as evaluated above.
5-HT quantitation
Free-floating sections through the lumbar enlargement (L1-3)
were rinsed in high-salt buffer (HSB), blocked with 5% NGS in
HSB containing 0.3% Triton X-100, incubated with a rabbit
anti-5HT antibody (1:40,000, Immunostar), rinsed thoroughly,
and incubated with an Alexa Fluor 488-conjugated antibody to
rabbit IgG made in goat (Invitrogen). A stacked image of the
ventral horn was captured (Ultraview Vox Spinning Disk
confocal microscope), and the integrated density of 5HT
immunoreactivity was quantified using ImageJ software.
Results were averaged over 10-12 sections per case and then
over the experimental group.
Statistics
Results are presented as group means ± SEM based on ≥ 6
rats per group. Statistical analyses used Mann-Whitney rank-
sum tests and, where appropriate, one-way and two-way
ANOVA. Scatter plots and Pearson’s product-moment
correlation coefficients were used to evaluate the relationship
between behavioral scores and lesion depth. Reported P
values are all two-tailed.
Results
Improvement of hindlimb function after inosine
treatment
Three-to-four weeks after a dorsal hemisection of the
thoracic spinal cord, rats treated with inosine performed
markedly better than saline-treated controls on tests of general
locomotion and fine-motor coordination. Inosine was equally
effective whether administered intracranially or intravenously.
The behavioral effects of inosine were seen in two independent
studies.
Study I: Intravenous vs. intracerebroventricular
delivery.  In the first of two studies, we compared the efficacy
of inosine delivered by direct infusion into the lateral ventricle
(intracerebroventricularly, i.c.v., n = 5) vs. intravenously (i.v., n
= 7). i.c.v. delivery of inosine has been shown to enhance CST
sprouting and to improve skilled use of an affected paw after
stroke or traumatic brain injury [18,20,21,27]. Clinically,
however, i.c.v. delivery is undesirable due to the risk of
intracranial infection, and we therefore investigated whether i.v.
delivery would be equally effective. Vehicle-treated controls in
the present study performed similarly regardless of whether
saline was delivered i.c.v. or i.v., and we therefore pooled
these animals to increase statistical reliability (final BBB score
for i.c.v. saline = 13.9 ± 1.3, for i.v. saline = 13.1 ± 1.1; average
= 13.5 ± 0.9; ladder rung walking test score for i.c.v. saline at 4
weeks = 19.9 ± 14.1%, for i.v. saline = 21.8 ± 8.6%; avg. =
21%).
All groups were severely impaired in open-field behavior one
day after surgery (BBB score ≤ 3: Figure 1A), possibly
reflecting spinal shock and secondary injury. Inosine-treated
rats (i.c.v., n = 13; i.v., n = 6) began to outperform controls by
two weeks and maintained this superiority for the remainder of
the study, averaging 4 points higher on the BBB scale at 4
weeks (Figure 1A: F = 21.35, P < 0.01). Rats performed
similarly after 4 weeks regardless of whether inosine was
delivered i.v. or i.c.v. (Figure 1A). Rats receiving inosine i.c.v.
appeared to recover somewhat faster than those receiving i.v.
inosine, possibly due to the greater bioavailability in the former
case. However, in our second study (see below), the rate of
recovery in the i.v. inosine group was comparable to that of the
i.c.v. inosine group in Study I. The difference in performance
between inosine- and saline-treated rats after 4 weeks
translates into a greater consistency of forelimb-hindlimb
coordination, plantar stepping, toe clearance, and positioning of
the hindlimb parallel to the direction of movement.
Unlike open-field behavior, which is largely independent of
the CST [28,29], the ladder rung-walking test requires this
pathway [23]. Inosine-treated rats outperformed controls on this
test from the second week on (P < 0.01, F = 14.56), and by 4
weeks, they were able to place their hindlimbs correctly on the
ladder rungs ≥ 50% of the time (Figure 1B). As with open-field
behavior, the final scores of inosine-treated rats on the ladder
rung test were nearly identical regardless of whether inosine
was delivered i.v. or i.c.v.
Study II: Confirmation of i.v. inosine effects.  After
completing the first study, we discovered that our BDA
injections infringed upon the forelimb motor area. This labeled
Inosine Improves Outcome after Spinal Cord Injury
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e81948
many axons that normally project to the cervical enlargement
and made it difficult to detect changes in collaterals that arise
from injured hindlimb axons. We therefore carried out a second
study in which we restricted BDA injections to the hindlimb area
as defined by electrophysiological mapping [25]. As noted
below, the new injections avoided labeling the forelimb motor
area, as judged by the scarcity of BDA-positive axons in the
cervical gray matter of control rats without SCI. Based on the
results of the first study and the greater clinical relevance of i.v.
vs. i.c.v. delivery, rats in the second study only received i.v.
infusions. Because of the problem with BDA placement in
Study I, all CST sprouting results are based on rats in Study II.
Rats receiving i.v. inosine (n = 20) again outperformed
saline-treated controls (n = 14) by a wide margin on the BBB
scale, scoring 5 points higher on average at the end of the 4-
week testing period (Figure 1C: F = 354, P < 0.001). Inosine-
treated rats in the second study were also superior to saline-
treated controls in the ladder rung-walking test. Both groups
averaged higher in the second study than in the first, but the
between-group difference remained strong (Study II average
scores for controls, 38.0 ± 1.4%; for inosine-treated rats, 67.1 ±
1.1%: Figure 1D; F = 227.8, P < 0.001). Between-group
comparisons are based upon rats that met the inclusion criteria
noted below.
In summary, inosine-treated rats performed markedly better
than saline-treated controls on tests of general locomotion and
sensorimotor integration after SCI. Rats performed equally well
regardless of whether inosine was delivered i.v. or i.c.v., and
the effects of i.v. inosine were reproducible across two
independent studies.
Inosine treatment does not affect lesion size
Histological analyses were carried out to investigate whether
inosine affects secondary injury and to verify that we had
completely transected the CST while leaving enough tissue
intact to allow for the formation of detour circuits [29].
Because even a small percentage of CST fibers can mediate
skilled behavior [30], it was essential to verify that this tract was
fully severed. This was accomplished by (a) visualizing the loss
of the CST during surgery; (b) verifying the complete
interruption of the CST in parasagittal sections through the
lesion site; (c) verifying the absence of BDA-positive axons in
coronal sections through the lumbar cord; and (d) excluding
rats whose lesions were < 50% the depth of the spinal cord
(Figure 2C-E). There were no significant between-group
differences in the percentage of rats excluded based on these
criteria (Figure 3A: 1 out of 28 saline-treated rats vs. 1 out of 39
Figure 1.  Inosine improves open-field behavior and skilled use of hindlimbs.  Behavioral studies were carried out in 2
separate cohorts of rats. General locomotor function was evaluated using the Basso-Beattie-Bresnahan (BBB) scale, whereas fine
motor coordination was tested using the ladder rung-walking test, scoring the percentage of steps in which either hindlimb was
placed on a rung without error. A, B. Study 1. Inosine was delivered either i.c.v. (black) or i.v. (blue); saline-treated controls are
shown in red. Note the superior performance of animals treated with either i.c.v. or i.v. inosine on the BBB (A) and the ladder rung
walking test (B). C, D, Study 2. Inosine and saline were delivered i.v. Inosine-treated rats again performed better than saline-treated
controls on both the BBB (C) and ladder-rung walking test (D) at weeks 3 and 4. *P < 0.05, **P < 0.01, ***P < 0.001. Data in all
figures represent group means ± SEM (Two-way ANOVA, Bonferroni a priori test).
doi: 10.1371/journal.pone.0081948.g001
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inosine-treated rats: X2 = 0.07, P ~ 0.8). Rats were also
excluded if lesions were ≥ 85% the depth of the spinal cord
based on earlier studies showing that transection of ≥ 90% of
the spinal cord prevents recovery of open-field behavior [29].
Our data show a marked drop-off in both open-field behavior
and the horizontal ladder rung walking test when lesions
exceeded 85% the depth of the cord despite inosine treatment
(Figure 4). There were no significant between-group
differences in the number of rats excluded using this second
criterion (3 out of 28 saline-treated rats vs. 9 out of 39 inosine-
treated rats: X2 = 1.12, P ~ 0.3; Figure 3A). To investigate
possible between-group differences in numbers of rats
excluded in the two groups further, we carried out a Mann-
Whitney rank sum test (non-parametric) of the lesion depths of
all animals and again found no significant difference between
the inosine- and saline-treated groups (P = 0.84). In light of the
appreciable motor function seen even in rats with the greatest
lesions (Figure 4), it is possible that many of the apparently
complete transections actually reflected tissue damage during
sectioning or histological processing. A Mann-Whitney rank
sum test of lesion depth vs. behavioral data that includes all
rats, including those that that fell outside of our lesion criteria,
continued to show highly significant differences between
inosine- and saline-treated rats (BBB: P < 0.0001; Ladder-rung
P < 0.0001). Animals remaining in the study after applying our
exclusion criteria had lesions that were, on average, ~ 70% the
depth of the cord regardless of treatment (Figure 3B). Saline
and inosine-treated groups were also similar to each other in
the cross-sectional areas of the lesions (Figure 3C). Together,
these results indicate that (a) inosine treatment did not affect
lesion size, and that (b) inter-group differences in performance
are not a consequence of differences in lesion size. After
applying our exclusion criteria, although there were clear inter-
group differences on both tests, there were no significant
within-group correlations between lesion depth and test
performance (Figure 4).
Inosine-treated rats show increased CST sprouting and
synaptic contacts
CST axons transected at the thoracic level sprout collateral
branches that can form synapses onto long propriospinal
interneurons (LPSNs) at the cervical level of the spinal cord,
forming a “detour circuit” that can partially restore cortical
control to the lumbar level in the case of incomplete SCI [9-11].
We investigated the sprouting of hindlimb CST axons at 4 loci
within the cervical spinal cord as shown in Figure 5B: (a)
immediately adjacent to the principal bundle of the CST, (b) at
the midline (M), (c) at a distance from the midline equal to the
width of the dorsomedial CST (Zone I), and (d) at twice the
latter distance (Zone II). Axon counts were normalized by the
total number of BDA-labeled axons in the dorsal CST for each
animal. In normal rats (n = 6), BDA labeling of the hindlimb
motor cortex resulted in fewer than 1% of all labeled axons in
the dorsal CST extending into the gray matter at the cervical
level. Inosine- and saline-treated rats were selected for detailed
histological analysis on a random basis and were coded so the
person doing the analyses was unaware of the animals’
treatment. Several cases were rejected based on inadequate
fixation or inadequate labeling of the CST.
CST transection and inosine treatment both increased axon
sprouting. In the absence of additional treatments, dorsal
hemisections of the thoracic spinal cord (n=5) increased the
number of hindlimb axons that extended into the cervical gray
matter two-fold (Figure 5F, P < 0.05; n.s. in G and H). Over and
above this change, rats receiving inosine (n = 7) showed twice
as many CST collaterals as saline-treated controls (Figure 5F -
H: all P ≤ 0.05). This increase was highest adjacent to the
dorsomedial CST, where the number of BDA-labeled axon
branches was ~ 5-fold higher than in intact animals, and
decreased at greater distances from the CST. Few CST fibers
crossed the midline in any group, though there was a small
increase after SCI (saline-treated compared to normal: P ≤
0.05) and a further increase with inosine treatment (P ≤ 0.01,
not shown).
We next investigated whether hindlimb CST axon collaterals
contact LPSNs. Following the methods of Bareyre et. al. [9], we
injected cholera toxin B fragment (CTB) into the lumbar
enlargement to retrogradely label LPSNs that project from the
cervical level of the spinal cord to the lumbar level, i.e., the
level of hindlimb control. We then counted bouton-like swellings
made by BDA-labeled CST axons onto CTB-labeled somata or
within 20 µm of their visible dendrites (Figure 6). As before,
results were normalized by the total number of BDA-positive
axons in the CST to account for inter-animal variability in the
overall extent of labeling. Axosomatic contacts were detected
far more frequently than axodendric contacts, most likely
because CTB labeling does not extend far into the dendritic
arbor of LPSNs (Figure 6) and because, even if dendritic
arbors were labeled, they may extend outside the plane of
section. Rats with SCI and saline treatment had 3 times as
many BDA-positive boutons that contacted CTB-positive
somata as normal controls (P < 0.01). The inosine-treated
group had twice as many of these contacts as saline-treated
controls (P < 0.01, Figure 6D) and a qualitatively similar,
though not statistically significant, increase in boutons within 20
µm of CTB+ dendrites (Figure 6E). Compared to normal rats,
rats receiving inosine after SCI had ~ 10-fold more contacts of
CST collaterals onto LPSN somata (Figure 6D, P ~ 0.001) and
4-fold more putative axodendritic contacts (Figure 6E, P <
0.05).
Conceivably, the increase in BDA-labeled axons contacting
CTB-labeled somata or dendrites noted above could reflect
increases in the number of LPSNs that get labeled in the
cervical enlargement following CTB injections in the lumbar
area. Inosine-treated rats showed ~ 15% more labeled LPSNs
following lumbar CTB injections than saline-treated controls,
but this difference did not achieve statistical significance and is
too small to account for the observed 3-fold difference in
numbers of contacts (Normal, mean ± SEM = 50.7 ± 2.6;
Saline, 42.8 ± 1.2; Inosine, 49.1 ± 1.8; differences not
significant, one-way ANOVA). These results also indicate that,
for rats that met our inclusion criteria, lesions did not greatly
disrupt LPSN projections that course through the ventrolateral
funiculus [31] and serve as the likely substrate for functional
recovery [9].
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We next examined whether BDA-labeled boutons that
contact LPSNs express synaptophysin and are therefore likely
to represent physiological synapses. Normal rats showed
almost no synaptophysin-positive CST contacts onto LPSNs
(Figure 7C), whereas rats with SCI treated with saline showed
significantly more (P < 0.01). Compared to the latter group, rats
treated with inosine after SCI had nearly 4 times as many
synaptophysin-positive boutons on CTB-positive LPSNs
(Figure 7, P < 0.05).
Restoration of serotonergic innervation in the lumbar
spinal cord
Quantitation of 5HT immunostaining in the ventral horns of
the lumbar spinal cord showed a 60% decline in levels of
Figure 2.  Interruption of the dorsal corticospinal tract (CST) after spinal cord injury (SCI).  A. Hindlimb CST axons were
labeled by injecting biotinylated dextran amine (BDA) into 9 sites in the hindlimb motor area of each hemisphere 4 weeks after SCI.
Rats survived 2 more weeks to allow for BDA transport. B. Identity of brain structures (from the atlas of Paxinos and Watson, 1997).
C. Parasagittal section through the thoracic cord shows labeled CST axons (arrowhead) rostral to the lesion (dashed lines). Note
the absence of labeled fibers distal to the injury. D, E. Transverse sections of the spinal cord at the cervical (D) and lumbar (E)
enlargements. Note heavy labeling at the cervical level (D, D') but absence of labeling in the lumbar cord (E, E'). Scale bar, 500 µm.
doi: 10.1371/journal.pone.0081948.g002
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serotonin immunoreactivity following dorsal hemisections (n =
12). Inosine-treated rats (n = 14) exhibited levels of serotonin
immunoreactivity comparable to those of normal rats (Figure
8). All cases used in this analysis had lesions depths that fell
within the criteria described above.
Dose-response study
A dose-response study demonstrated high levels of recovery
in rats treated with 60% less inosine than in the above studies.
In addition to the dosage tested above (260 mM), we tested i.v.
inosine at nominal concentrations of 30 mM (n = 5) and 100
mM (n = 6). For statistical robustness, we included in the
analysis rats that received 0 or 260 mM i.v. inosine in Studies 1
and 2 (total n = 17 for saline and n = 16 for 260 mM inosine). At
30 mM, inosine treatment did not improve outcome on either
the BBB scale or the horizontal ladder rung-walking test.
Although rats treated with 100 mM inosine showed a slow initial
rate of recovery, their scores on the BBB scale and ladder-walk
after 4 weeks were similar to those of rats receiving 260 mM
inosine (P < 0.01 compared to saline-treated controls, both
tests: Figure 9).
Discussion
Although most neural pathways cannot regenerate long
distances after SCI in mature mammals, both injured and
uninjured axons are able to extend collateral branches and
form compensatory circuits that help improve outcome after
incomplete spinal lesions [9,12,32-35]. Clinically, such
sprouting is thought to contribute to the partial recovery that is
often seen in patients with incomplete lesions [36]. In the
present study, rats treated with inosine showed considerably
more axon sprouting and more corticospinal-LPSN synapses
Figure 3.  Inosine does not affect lesion size.  A. Depth of lesions for all animals in Studies 1 and 2 (bars show group means;
dashed lines show exclusion limits). B. lesion depth after excluding rats in which the lesion was either ≤ 50% or > 85% the depth of
the spinal cord. C. Area of lesions (percentage of tissue lost within an 8 mm segment of spinal cord centered at the lesion
epicenter). Inosine and saline-treated groups did not differ from each other in lesion depth or area (One-way ANOVA, Dunnet a
priori test).
doi: 10.1371/journal.pone.0081948.g003
Figure 4.  Behavioral outcome depends upon treatment but not depth of lesion.  Scattergrams show open field behavior (A)
and ladder rung scores (B) as a function of lesion depth. Blue dots represent rats treated with either i.c.v. or i.v. inosine, and red
dots are rats treated with saline; dotted lines show the upper and lower bounds of our exclusion criteria. Within these bounds,
inosine-treated rats out-performed controls, but there is no significant correlation (n.s.) between performance and lesion size.
Performance on both tests falls off for lesions outside the lower limit for inclusion in the study.
doi: 10.1371/journal.pone.0081948.g004
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after incomplete SCI than saline-treated rats, along with
superior control of hindlimb function.
The corticospinal tract (CST) mediates skilled movements of
the distal extremities and has been studied extensively due to
its importance for voluntary control in humans [37]. In mice and
rats, CST damage has only a transitory effect on general
locomotion but severely impairs skilled use of the limbs [23].
Even without special treatments, CST axons sprout collateral
branches after SCI that can form novel circuits, and this
process can be augmented by physiological activity, trophic
factors, or counteracting cell-extrinsic inhibitors of axon growth
[11,38-45]. Following CST injury at the mid-thoracic level,
severed axons arising from pyramidal cells in the hindlimb
motor cortex sprout collateral branches rostral to the injury site
that synapse onto long propriospinal interneurons in laminae V-
VII of the cervical cord, forming “detour circuits” that partially
restore cortical control to the hindlimbs [9-11,46]. In conformity
with these studies, we observed a two-fold increase in CST
sprouting after dorsal hemisections in saline-treated controls.
Inosine-treated animals showed twice as much axon sprouting
as saline-treated controls and 4 times the number of synaptic
contacts between CST collaterals and long propriospinal
interneurons (LPSNs) that project from the cervical
enlargement to the lumbar level. The role of this circuit in
functional recovery has been demonstrated by trans-synaptic
labeling and electrophysiology [9,44]. We observed many more
axosomatic than axodendritic contacts, which may be a
consequence of the failure of the retrograde tracer (CTB) to fill
distal portions of dendrites, or may be characteristic of these
novel connections. At a functional level, although untreated
controls showed partial recovery 4 weeks after SCI, the
recovery in inosine-treated animals was much stronger.
Compared to saline-treated controls, rats treated with inosine
showed much greater accuracy in hindlimb placement in the
ladder-rung walking test, a measure of cortical control of the
distal extremities [23], and a 4-5 point difference on the BBB
scale. Unlike the CST, LPSNs can regenerate axons when
transected [47]. However, our retrograde labeling studies
suggest that inosine did not greatly alter the projections of
these neurons.
Because a small residue of CST fibers can mediate
appreciable skilled hindlimb movements [29], we excluded rats
Figure 5.  Inosine increases CST axon branching in the cervical spinal cord.  A. Transverse section through the cervical
enlargement. B. BDA-labeled CST collaterals were quantified at the border of the main (dorsomedial) CST (B), the midline (M), and
at distances I and II from the midline. C - E, SCI alone increases CST sprouting in the gray matter compared to a sham-treated
controls (D vs. C), and inosine enhances it further (E). F - H, Quantitation of CST sprouting into the gray matter at the indicated loci.
#P < 0.05, ##P < 0.01 compared to sham-operated controls; *P < 0.05, ** P < 0.01 compared to saline-treated rats with SCI. Axon
counts were normalized by the total number of axons counted in the main CST at the cervical level (Mann-Whitney test).
doi: 10.1371/journal.pone.0081948.g005
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Figure 6.  Inosine increases CST contacts onto LPSNs.  A.
Transverse section of an inosine-treated animal though the
cervical enlargement shows position of LPSNs (boxes). B, C.
Enlargement of areas in (A) show LPSNs (red) that project to
the lumbar enlargement. B', C'. Higher magnification of cells in
B and C. Arrowheads show BDA-labeled CST collaterals
(green) contacting an LPSN soma (B') and proximal dendrites
(C'). D, E, Quantitation of CST synapses upon LPSN somata
and within 20 µm of labeled dendrites. SCI alone increases
axosomatic synapses compared to sham-operated controls,
and inosine increases the number of these to a greater extent
(D). Inosine also increases putative axodendritic contacts
compared to normal animals (E). *P < 0.05 compared to saline
treatment, #P < 0.05, ##P < 0.01 compared to sham-operated
controls (Mann-Whitney).
doi: 10.1371/journal.pone.0081948.g006
Figure 7.  Inosine increases synaptic contacts between
CST collaterals and LPSNs.  A. Spinning-disc confocal image
shows BDA-labeled boutons (red) in the cervical enlargement
that arise from CST axon collaterals and express the
presynaptic protein synaptophysin (green). B. Confocal image
shows CST boutons co-localized with synaptophysin (green)-
positive contacts upon a CTB-labeled LPSN (blue). Side
images show co-localization in the x-z and y-z planes. C.
Quantitation of synaptophysin- and BDA-positive boutons on
LPSN somata. SCI alone increases synaptic contacts on
LPSNs, and inosine causes a further 4-fold increase. Data are
normalized by the total number of labeled axons in the main
bundle of the CST. *P < 0.05 compared to saline treatment, ##P
< 0.01 compared to normal control (Mann-Whitney test).
doi: 10.1371/journal.pone.0081948.g007
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whose lesions spared axons in the dorsal CST. We also
excluded rats in which lesions were > 85% the depth of the
cord, as such lesions would damage the ventrolateral funiculus
[31] that carries propriospinal axons that are important for the
recovery of skilled hindlimb control [9]. Our behavioral analysis
confirmed the inability of rats to recover skilled ladder rung-
walking after such extensive lesions. Following the exclusion of
animals based on these criteria, inosine- and saline-treated
groups were closely matched for lesion size and area, and the
observed differences in behavior can therefore not be
attributed to differences in tissue sparing. In conformity with
these results, several prior studies have reported beneficial
Figure 8.  Inosine increases serotonergic input to the lumbar spinal cord.  A. Schematic diagram of the lumbar enlargement.
Box delineates area of 5-HT analysis in the ventral horn. B. Integrated intensity of 5-HT immunofluorescence. SCI decreases 5-HT
immunofluorescence compared to normal controls. i.v. inosine restores 5-HT levels back to normal (F = 10.93; **P < 0.01 compared
to saline treatment, †P < 0.05 compared to sham-operated controls: One-way ANOVA, Dunnet a priori test). C - E.
Photomicrographs show serotonergic fibers in the lumbar enlargement of sham-operated rats (C) and after SCI in rats treated with
i.v. saline (D) or i.v. inosine (E).
doi: 10.1371/journal.pone.0081948.g008
Figure 9.  Dose-response relationship for intravenous inosine.  A, B. Behavioral results 4 weeks after SCI. The effects of
inosine reach a plateau at 100 mM in both the open-field (A) and ladder rung walking (B) tests. C, D. Behavioral test results over the
4 week test period. *P < 0.01; **P < 0.01; ***P < 0.01 (One-way ANOVA, Dunnet a priori test (a, b); two-way ANOVA, Bonferroni a
priori test (c, d)).
doi: 10.1371/journal.pone.0081948.g009
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effects of inosine after stroke or traumatic brain injury in the
absence of neuroprotection [20,21,27]. However, one study
reported inosine to be neuroprotective when administered prior
to SCI [48].
Descending serotonergic projections originate in the
medullary raphe nuclei, course through the ventrolateral and
ventral funiculi, and terminate in the ventral horn and other
parts of the spinal gray matter [49]. The raphespinal pathway
contributes to maintaining posture, initiating movement, and
modulating the central pattern generator (Jordan et al., 2008),
and is critical for the recovery of general locomotion after SCI
[44,50-54]. Recovery of locomotion after SCI can also be
mediated in part by constitutively active 5HT2 receptors when
raphespinal input is eliminated [54]. As expected, our lesions
strongly reduced serotonergic input to the ventral gray matter
of the lumbar spinal cord [6,44,55], but inosine treatment
restored 5-HT immunoreactivity to normal levels. These rats
displayed greater forelimb-hindlimb coordination and limb
placement than saline-treated controls, returning to near-
normal levels of performance after 4 weeks. However, because
the recovery of locomotion depends upon multiple systems that
course through the ventral spinal cord [23], and because
serotonergic receptors can be constitutively active, the extent
to which the improvements in locomotion seen here depended
upon raphespinal sprouting per se is uncertain. Raphespinal
sprouting has also been linked to improvements in locomotion
after counteracting inhibitory proteins associated with myelin
[6,44,55].
Inosine is a naturally occurring metabolite of adenosine that
can diffuse across the neuronal cell membrane and activate
Mst3b, a protein kinase that is part of a cell-signaling pathway
that controls axon outgrowth [13,14]. Low micromolar
concentrations of inosine induce axon outgrowth from
embryonic cortical neurons and other neural populations in
culture [13,15,16,20], and in vivo, inosine stimulates axon
sprouting from CST axons originating in the undamaged
hemisphere after a unilateral stroke or traumatic brain injury
[18,20,21,27]. Inosine was also reported to promote CST
sprouting after unilateral transection of the contralateral CST
[56], although this latter finding was not replicated in another
study [57], possibly due to important methodological
differences [58].
Besides its effects on axon sprouting, inosine has been
reported to suppress the response of cortical neurons to
glutamate [59], enhance inhibition via benzodiazepine
receptors [60], limit the production of inflammatory cytokines
[61,62], and attenuate hypoxia-induced astrocyte death [63,64].
Uric acid, a primary metabolite of inosine, prevents
peroxynitrite-induced protein damage, protects the blood-brain
barrier, and has potent anti-inflammatory effects [65,66].
Importantly, inosine has a history of safe use in humans. It is
used in cardiac patients in several countries [67] and is often
taken by athletes, though with questionable benefit [68]. Based
upon the effectiveness of the inosine metabolite uric acid as an
antioxidant, clinical trials are underway using oral inosine in
Parkinson’s Disease http://clinicaltrials.gov/ct2/show/
NCT00833690 and multiple sclerosis http://clinicaltrials.gov/ct2/
show/NCT00067327.
We found inosine to reach maximal effectiveness at ~ 40
mg/da/kg i.v. This is somewhat higher than the dose commonly
administered in China i.v. for multiple indications (4-20
mg/da/kg: Dr. Gong Ju, personal communication) but lower
than the recommended oral dose as a health supplement
(~150 mg/kg/da). Inosine is effective at a much lower dose
when delivered directly into the brain through an indwelling
ventricular catheter, but this route is clinically undesirable due
to risk of cerebral infection. The efficacy of i.v. administration is
consistent with earlier studies showing appreciable
permeability through the blood-brain-barrier [69,70].
Although this study has demonstrated inosine’s efficacy in a
dorsal spinal cord hemisection model, transection of defined
fiber tracts seldom occurs clinically, and a contusion model of
injury would be valuable to further assess the value of inosine
in a clinical setting. In addition, although our results show an
effect of inosine on the formation of novel CST-LPSN contacts,
it is likely that other pathways also contribute to the observed
functional improvements. Among the pathways damaged by a
dorsal hemisection is the rubrospinal tract, which is important
for volitional control, though we have not examined changes in
this pathway. In addition, our results show extensive sprouting
of the raphespinal tract, which is important for general
locomotion and right-left coordination. It might be noted,
however, that the CST sprouting that we report here probably
underestimates the formation of novel CST-LPSN synapses
since we were only able to observe CST contacts onto LPSN
somata and proximal dendrites. Possible contacts onto the
distal dendritic arbor were not visualized due to the limited
filling of cell bodies by retrogradely transported CTB.
Because of its demonstrated efficacy in multiple animal
models of neurological injury (SCI, stroke, traumatic brain
injury), its clinical safety in humans, and the feasibility of i.v.
delivery, inosine would appear to be a good candidate to
advance towards clinical trials for treating patients with SCI,
perhaps in combination with complementary treatments.
Inosine delivered i.c.v. potentiates the effects of environmental
enrichment, training, and a Nogo receptor antagonist after
unilateral cortical damage [20,27], and it may similarly augment
the effects of these and other treatments that improve outcome
after SCI such as physiological activity or stem cell implants
[6,8].
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